Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats

Full text
Author(s):
Show less -
Peres, Fernanda F. ; Leyin, Raquel ; Suiama, Mayra A. ; Diana, Mariana C. ; Gouvea, Douglas A. ; Almeida, Valeria ; Santos, Camila M. ; Lungato, Lisandro ; Zuardi, Antonio W. ; Hallak, Jaime E. C. ; Crippa, Jose A. ; D'Almeida, Vania ; Silva, Regina H. ; Abilio, Vanessa C.
Total Authors: 14
Document type: Journal article
Source: FRONTIERS IN PHARMACOLOGY; v. 7, SEP 28 2016.
Web of Science Citations: 6
Abstract

Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats. Male Wistar rats received four injections of CBD (0.5 or 5 mg/kg) or vehicle (days 2-5). On days 3 and 5, animals received also one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9, we evaluated animals' performance on the plus-maze discriminative avoidance task, for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in catalepsy behavior and in oral movements - but not the decrease in locomotion induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate motor and cognitive impairments induced by reserpine, suggesting the use of this compound in the pharmacotherapy of Parkinson's disease and tardive dyskinesia. (AU)

FAPESP's process: 10/07994-3 - Role of dopamine and endocannabinoid systems in an animal model of schizophrenia: the spontaneously hypertensive rat (SHR)
Grantee:Vanessa Costhek Abílio
Support type: Regular Research Grants
FAPESP's process: 15/03354-3 - PATHOPHYSIOLOGICAL MECHANISMS AND NEUROPROTECTIVE INTERVENTIONS IN A PROGRESSIVE ANIMAL MODEL OF PARKINSON'S DISEASE
Grantee:Regina Helena da Silva
Support type: Regular Research Grants